Paquinimod ( DrugBank: Paquinimod )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 49 | 全身性エリテマトーデス | 3 |
| 51 | 全身性強皮症 | 3 |
49. 全身性エリテマトーデス
臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00997100 (ClinicalTrials.gov) | August 2009 | 16/10/2009 | Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE) | An Exploratory Study to Evaluate Changes in Disease Activity and Biomarkers During Treatment With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | Drug: paquinimod (ABR-215757) | Active Biotech AB | NULL | Completed | 18 Years | N/A | Both | 13 | Phase 2 | Denmark;Sweden |
| 2 | EUCTR2009-011245-55-DK (EUCTR) | 08/06/2009 | 27/04/2009 | An Exploratory Study to Evaluate Changes in Disease Activity and Biomarkers During Treatment With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE). Final Protocol dated 2009-03-16. Protocol Amendment 1 dated 2009-10-13. Protocol Amendment 2 dated 2009-12-02 | An Exploratory Study to Evaluate Changes in Disease Activity and Biomarkers During Treatment With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE). Final Protocol dated 2009-03-16. Protocol Amendment 1 dated 2009-10-13. Protocol Amendment 2 dated 2009-12-02 | Systemic Lupus Erythematosus (SLE) MedDRA version: 9.1;Level: LLT;Classification code 10042945;Term: Systemic lupus erythematosus | Product Name: ABR-215757 Product Code: ABR-215757 INN or Proposed INN: paquinimod | Active Biotech Research AB | NULL | Not Recruiting | Female: yes Male: yes | 20 | Denmark;Sweden | |||
| 3 | EUCTR2009-011245-55-SE (EUCTR) | 06/05/2009 | 18/03/2009 | An Exploratory Study to Evaluate Changes in Disease Activity and Biomarkers During Treatment With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE). Final Protocol dated 2009-03-16, Protocol Amendment 1 dated 2009-10-13, Protocol Amendment 2 dated 2009-12-02 | An Exploratory Study to Evaluate Changes in Disease Activity and Biomarkers During Treatment With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE). Final Protocol dated 2009-03-16, Protocol Amendment 1 dated 2009-10-13, Protocol Amendment 2 dated 2009-12-02 | Systemic Lupus Erythematosus (SLE) | Product Name: ABR-215757 Product Code: ABR-215757 INN or Proposed INN: paquinimod | Active Biotech Research AB | NULL | Not Recruiting | Female: yes Male: yes | 20 | Denmark;Sweden |
51. 全身性強皮症
臨床試験数 : 523 / 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01487551 (ClinicalTrials.gov) | December 2011 | 6/12/2011 | An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod) | An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod) | Systemic Sclerosis | Drug: paquinimod | Active Biotech AB | NULL | Completed | 18 Years | N/A | Both | 9 | Phase 2 | Germany;Sweden;Switzerland |
| 2 | EUCTR2011-001667-44-DE (EUCTR) | 28/09/2011 | 26/09/2011 | A study to evaluate biomarkers and safety in scleroderma patients treated with ABR-215757 (paquinimod) | An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with ABR-215757 (paquinimod) | Systemic Sclerosis MedDRA version: 14.1;Level: PT;Classification code 10042953;Term: Systemic sclerosis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 14.1;Level: LLT;Classification code 10036814;Term: Progressive systemic sclerosis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: paquinimod Product Code: ABR-215757 INN or Proposed INN: paquinimod | Active Biotech AB | NULL | Not Recruiting | Female: yes Male: yes | 20 | Germany;Switzerland;Sweden | |||
| 3 | EUCTR2011-001667-44-SE (EUCTR) | 28/06/2011 | 18/05/2011 | An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with ABR-215757 (paquinimod) | An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with ABR-215757 (paquinimod) | Systemic Sclerosis MedDRA version: 14.0;Level: PT;Classification code 10042953;Term: Systemic sclerosis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 14.0;Level: LLT;Classification code 10036814;Term: Progressive systemic sclerosis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: paquinimod Product Code: ABR-215757 INN or Proposed INN: paquinimod | Active Biotech AB | NULL | Not Recruiting | Female: yes Male: yes | 20 | Germany;Switzerland;Sweden |